June 7, 2026Diabetes
2819-LB: Adoption of GLP-1RA and SGLT2i Drug Classes among Patients with Cardiovascular or Renal Indications: Evolution of Prescribing Patterns over Time
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial evaluates prescription trends of GLP-1RA and SGLT2i in adults with diabetes, suggesting targeted interventions are needed.
Key Points
- The study aims to evaluate the prescribing patterns of GLP-1RA and SGLT2i among patients with type 2 diabetes and cardiovascular or renal indications.
- Analyzed EHR data from 7,917 adults with type 2 diabetes and relevant indications.
- Used cluster-robust linear probability modeling to assess prescription likelihood.
- Examined changes in prescribing patterns over three time periods: 2016-2018, 2019-2021, and 2022-2023.
- CVD or DKD increased prescription probability by 6.4%, obesity by 12.6%, and high HbA1c by 16.3% (p<0.001 for all).
- Obesity significantly accelerated prescribing in the 2022-2023 period by 7% (p=0.01 for interaction).
- In 2022-2023, estimated prescription rates were lower for CVD or DKD (46.7%) compared to obesity (50.9%) and high HbA1c (50.7%).
Cite This Study
TORRES et al. (2026) studied this question.